WuXi XDC Cayman, Inc. (2268) AI Stock Analysis

• Market Cap: HK$53.89B
• Dividend Yield: N/A
• Average Volume (3M): 5.44M
• Price to Earnings (P/E): 46.3
• Beta (1Y): 0.88
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 2,041
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.97
• Shares Outstanding: 1,202,859,100
• 10 Day Avg. Volume: 5,268,965
• 30 Day Avg. Volume: 5,440,974
• PEG Ratio: 0.00
• Price to Book (P/B): 87.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.03K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$48.69
• Price Target Upside: 8.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 75 Outperform
• Price Target: HK$50.00 ▲(11.61%Upside)

WuXi XDC Cayman, Inc. exhibits strong financial fundamentals and positive technical indicators, indicating robust business growth and market confidence. However, the company's high valuation and negative free cash flow pose risks. Investors should be aware of potential volatility due to the technical indicators approaching overbought levels.

WuXi XDC Cayman, Inc. Business Overview & Revenue Model

Company Description

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

How the Company Makes Money

WuXi XDC Cayman, Inc. generates revenue through a service-based business model, offering end-to-end solutions for the development and production of antibody-drug conjugates. The company's key revenue streams include fees from research and development services, manufacturing services, and licensing agreements. By collaborating with pharmaceutical and biotechnology companies, WuXi XDC assists in bringing novel therapies to market, earning revenue from both upfront payments and milestone payments associated with successful project advancement. Additionally, strategic partnerships and alliances within the biopharmaceutical industry play a significant role in expanding the company's reach and enhancing its service offerings.

WuXi XDC Cayman, Inc. Financial Statement Overview

Summary

WuXi XDC Cayman, Inc. shows strong revenue and profit growth with efficient operations, supported by a robust equity position. However, significant capital expenditures leading to negative free cash flow could pose liquidity challenges if not addressed.

Income Statement

WuXi XDC Cayman, Inc. has demonstrated impressive revenue growth, with a 90.8% increase from 2023 to 2024 and a substantial gross profit margin of 30.6% in 2024. The net profit margin stands at a robust 26.4%, indicating strong profitability. EBIT and EBITDA margins are also strong at 23.4% and 32.9%, respectively, underscoring efficient operations.

Balance Sheet

The company has a solid equity position with a debt-to-equity ratio of 0.07, indicating low leverage. The return on equity is strong at 16.1%, reflecting effective use of shareholder funds. An equity ratio of 72.8% suggests a stable financial foundation with a substantial portion of assets funded by equity.

Cash Flow

Operating cash flow has increased, yet the free cash flow remains negative at -$787.95 million due to significant capital expenditures. However, the operating cash flow to net income ratio of 0.67 reflects reasonable cash conversion from earnings, while the free cash flow to net income ratio is negative, indicating pressure on cash flow.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.80B	4.05B	2.12B	990.42M	311.13M	96.35M
	Gross Profit
865.49M	1.24B	559.56M	261.08M	113.49M	8.08M
	EBIT
575.14M	948.53M	365.50M	242.09M	77.90M	32.66M
	EBITDA
659.16M	1.33B	420.28M	272.90M	96.89M	46.12M
	Net Income Common Stockholders
594.55M	1.07B	283.54M	155.73M	54.93M	26.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.48B	3.97B	4.05B	734.97M	26.32M	28.39M
	Total Assets
7.27B	9.12B	6.74B	2.50B	879.75M	408.47M
	Total Debt
68.65M	496.43M	2.84M	77.18M	24.59M	0.00
	Net Debt
-3.41B	-1.43B	-4.04B	-257.79M	-1.73M	-28.39M
	Total Liabilities
1.28B	2.48B	1.28B	1.02B	858.87M	32.79M
	Stockholders Equity
5.99B	6.64B	5.45B	1.48B	20.88M	375.68M
Cash Flow		Free Cash Flow
-854.85M	-787.95M	-206.51M	-135.74M	7.23M	-32.03M
	Operating Cash Flow
-51.45M	717.22M	332.85M	251.82M	59.14M	20.85M
	Investing Cash Flow
-642.90M	-3.33B	-91.23M	-1.28B	-51.59M	-52.42M
	Financing Cash Flow
3.64B	475.36M	3.52B	1.33B	22.34M	69.12M

WuXi XDC Cayman, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 44.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2268, the sentiment is Positive. The current price of 44.8 is above the 20-day moving average (MA) of 40.20, above the 50-day MA of 37.86, and above the 200-day MA of 30.46, indicating a bullish trend. The MACD of 1.82 indicates Negative momentum. The RSI at 67.38 is Neutral, neither overbought nor oversold. The STOCH value of 82.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2268.

WuXi XDC Cayman, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	75 Outperform	HK$53.89B	46.30	17.75%	―	―	―
Sector *	58 Neutral	$4.89B	18.48	-17.00%	7.21%	13.61%	-24.47%
WXIBF		$14.51B	28.26	8.17%	―	―	―
2263	68 Neutral	HK$167.00M	50.61	0.92%	―	31.76%	-35.29%
2262	44 Neutral	HK$1.52B	831.25	0.59%	―	3.34%	―
2265		HK$1.02B	15.67	12.01%	―	―	―
2266		HK$116.00M	4.96	20.60%	―	―	―

WuXi XDC Cayman, Inc. Corporate Events

WuXi XDC Cayman Inc. Reschedules 2024 AGM Date

WuXi XDC Cayman Inc., a company incorporated in the Cayman Islands, has announced a change in the date of its 2024 annual general meeting (AGM). Originally scheduled for June 25, 2025, the AGM will now take place on June 27, 2025, due to administrative reasons. Consequently, the book closure period for determining shareholders’ eligibility to attend and vote has been adjusted to June 24-27, 2025.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

WuXi XDC Cayman Inc. Announces Annual General Meeting and Strategic Resolutions

WuXi XDC Cayman Inc. has announced its Annual General Meeting scheduled for June 27, 2025, in Wuxi City, China. The meeting will address several key agenda items, including the reception of audited financial statements, re-election and appointment of directors, and authorization of directors’ remuneration. Additionally, the company seeks approval for a mandate to issue and allot shares, reflecting its strategic focus on expanding its operational capabilities and enhancing shareholder value.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

WuXi XDC Cayman, Inc. Announces 2024 Share Scheme Grant

WuXi XDC Cayman, Inc. has approved the grant of 5,387,735 restricted shares to 287 grantees, including directors and employees, under its 2024 Share Scheme. This initiative aims to motivate employees by providing a personal stake in the company, with shares vesting over a five-year period. The grant is based on work performance and potential, without additional performance targets, and includes a clawback mechanism for cases of misconduct.